牛牛AI助理已提取核心訊息
Avalo Therapeutics, Inc., a biotechnology company, has been the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC) as of December 31, 2023. The filing was made by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, indicating a shared voting and dispositive power over 2,500 shares of Avalo Therapeutics' common stock, issuable upon exercise of warrants. These shares represent a 0.3% ownership of the class. The filing entities have entered into a Joint Filing Agreement, suggesting a coordinated approach to the filing. The address for Point72 Asset Management and Point72 Capital Advisors is in Stamford, CT, and both entities are organized under the laws of Delaware. Steven A. Cohen is identified as a United States citizen. The filing...Show More
Avalo Therapeutics, Inc., a biotechnology company, has been the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC) as of December 31, 2023. The filing was made by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, indicating a shared voting and dispositive power over 2,500 shares of Avalo Therapeutics' common stock, issuable upon exercise of warrants. These shares represent a 0.3% ownership of the class. The filing entities have entered into a Joint Filing Agreement, suggesting a coordinated approach to the filing. The address for Point72 Asset Management and Point72 Capital Advisors is in Stamford, CT, and both entities are organized under the laws of Delaware. Steven A. Cohen is identified as a United States citizen. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics and were not acquired in connection with any transaction having such purpose or effect. The filing includes a certification of accuracy and completeness signed by Jason M. Colombo, an authorized person for all three reporting entities.
截至2023年12月31日，生物技術公司Avalo Therapeutics, Inc. 已成爲最近向美國證券交易委員會（SEC）提交的附表13G/A文件的主題。該文件由Point72資產管理有限責任公司、Point72 Capital Advisors, Inc.和Steven A. Cohen提交，表明行使認股權證後可發行的2,500股Avalo Therapeutics普通股擁有共同的投票權和處置權。這些股份佔該類別0.3％的所有權。申報實體已簽訂聯合申報協議，建議採用協調的申報方法。Point72資產管理公司和Point72 Capital Advisors的地址位於康涅狄格州斯坦福德...展開全部
截至2023年12月31日，生物技術公司Avalo Therapeutics, Inc. 已成爲最近向美國證券交易委員會（SEC）提交的附表13G/A文件的主題。該文件由Point72資產管理有限責任公司、Point72 Capital Advisors, Inc.和Steven A. Cohen提交，表明行使認股權證後可發行的2,500股Avalo Therapeutics普通股擁有共同的投票權和處置權。這些股份佔該類別0.3％的所有權。申報實體已簽訂聯合申報協議，建議採用協調的申報方法。Point72資產管理公司和Point72 Capital Advisors的地址位於康涅狄格州斯坦福德，這兩個實體均根據特拉華州法律組建。史蒂芬·科恩被確定爲美國公民。該文件稱，收購這些股份不是爲了改變或影響Avalo Therapeutics的控制權，也不是與任何具有此類目的或效果的交易有關而收購的。該文件包括一份由所有三個申報實體的授權人Jason M. Colombo簽署的準確性和完整性證明。
有用
沒用